Abstract: For the development of intelligent implant systems hydrogels (HG) from crosslinked ionic liquids feature a high potential to be utilised as a drug depot. Biocompatibility of the HGs is one key prerequisite for biomedical applications. HGs were polymerised from a variety of different ionic monomers based on methacrylate, methacrylamide, styrene or vinyl imidazolium derivatives in aqueous solution. N,N'-methylenebisacrylamide was used as crosslinker. CellQuanti-Blue™ Cell Viability Assay Kit was implemented to proof viability of L929 mouse fibroblasts. The predominant part of the HG eluates generated only a marginal reduction of less than 15% cell viability at 100% eluate concentration. This underlines the excellent suitability of these HGs for biomedical applications and revealed some promising candidates for the development of drug depots for implants.
Introduction
Hydrogels functionalised for drug delivery have a broad spectrum of application overarching drug eluting stent technology [1] and drug-coated balloons [2] for cardiovascular therapy but also injectable biomaterials [3] for ophthalmologic therapies [4] , bone tissue engineering [5] and local cancer therapy [6] .
Particularly as coatings on implants, biocompatible HGs can provide stringent requirements such as rapid wound healing and long-term functionality (e.g. preventing a stent from thrombosis or restenosis). These requirements can be met through HGs, which can incorporate and release active ingredients [7, 8] .
Local drug release from HGs, when applied for hydrophilic drugs, is relatively fast. Thus, interactions between the drug molecule and the HG backbone are required for prolonging drug release. This can be achieved by either chemical bonding or physical interactions. For the latter the most prominent example is the ionic interaction. Therefore, polyelectrolyte hydrogels (PEHG) are a promising strategy for the retention of the drug release via ionic interactions [9] .
The additional combination of PEHGs with thermoresponsive poly(N-isopropylacrylamide) (pNIPAAm) opens up the possibility to achieve a temperature-controlled drug release. Strong effects on volumetric changes and mechanical properties as well as drug release with these hybrid hydrogels (HHG) were already observed [10] .
As a first step towards a comparative evaluation of possible HG candidates, the biocompatibility was assessed in this work. For this purpose the effect of different HG on the cell viability of L929 mouse fibroblasts was investigated by in vitro eluate tests.
Materials and methods

Hydrogel polymerisation
Ammonium peroxodisulfate (APS), N,N′ methylenebis(acrylamide) (MBis), N-isopropylacrylamide (NIPAAm) and N'-tetramethyl-ethylenediamine (TEMED) were purchased from Sigma Aldrich and used as received. 1-vinyl-3-ethylimidazolium bromide [11, 12] , 1-vinyl-3-isopropylimidazolium bromide [13] and 2-hydroxypropyl methacrylamide [14] were synthessed according to a literature procedures. All other monomers were purchased from Sigma Aldrich or TCI and used as received.
General procedure for the PEHG synthesis: The monomer and the according amount of MBis (2 mol%) were dissolved in deionised water and the total monomer concentration was adjusted to the required value. Subsequently, the according amount of APS solution was added (0.1 mol% of total monomer amount), using a surplus of the amount of inhibitor contained in the respective monomer. The reaction solution was filled into a syringe and degassed with argon for 10 to 15 min. To initiate the polymerisation, the according amount of TEMED solution was added (1.9 mol% of total monomer amount) and after airtight closing of the syringe the polymerisation mixture was incubated at room temperature for five days. Subsequently, the HGs were swollen in an excess of deionised water (1 L) and thoroughly rinsed in water by regularly exchanging the supernatant water. General procedure for the HHG synthesis: By using NIPAAm, the monomer 1-vinyl-3-isopropyl-imidazolium bromide and MBis as crosslinking agent hydrogel samples of PIL, pNIPAAm and PIL/pNIPAAm 50/50wt% have been prepared. The MBis amount was kept constant with 1.3% related to the amount of IL or NIPAAm. TEMED is used with APS to catalyze the polymerization and was added subsequently. Defined masses were mixed and dissolved in distilled water as described in detail in [10] . Subsequently, the HHGs (1 g) were swollen in deionised water (10 mL), whereby the medium was changed three times within 72 h.
Cell culture
L929 mouse fibroblasts (CCL-1, ATCC) were cultured in DMEM (PAN BIOTECH, Aidenbach, Germany) with 4.5 mg Glucose, 10 % fetal calf serum (FCS), 1 % Penicillin/Streptomycin and 3.7 g/l NaHCO 3 .
For screening tests 2x10 4 L929 mouse fibroblasts were seeded in a 96-well microtiter plate with 200 µL culture medium per well and incubated under cell culture conditions (37 °C, 5% CO2) for 24 hours.
Cell viability assay
CellQuanti-Blue Cell Viability Assay Kit (BioAssay systems, Hayward, CA, USA) was implemented to proof viability L929 mouse fibroblasts. Water expanded hydrogels were eluted in serum free culture medium under identical conditions. After elution, 10% FCS (fetal calf serum) was added to the sterile-filtered medium, and a dilution series was prepared. Subsequently, the cell culture media of the raised cells were exchanged with 200 μL of each eluate dilutions and incubated for 48 hours (37 °C, 5% CO 2 ). Following that incubation, the eluate dilutions were exchanged with 200 µL of fresh cell culture medium with 10 % CellQuanti-Blue supplement and incubated for 2 hours under same conditions. The reductive activity of the cells conducts the metabolic turnover from resazurin to the fluorescent resorufin (absorption 544 nm, emission 590 nm) which was detected with the Fluostar optima (BMG LABTECH, Ortenberg, Germany). 
Statistical analysis
For all HGs every eluate dilution was prepared in quadruplicate. Replicates were tested for normal distribution and subjected to a Nalimovs' test for outliers. Means and standard errors (SEM) were calculated and statistic significances were determined with a One-way analysis of variance in Sigma Plot (significance thresholds: * p < 0.05, **< 0.01, *** p < 0.001).
Results
Cell viability in PEHG eluates
Seven of ten PEHG eluates (PEHG 1, 3, 4, 6, 7, 8, 9) cause only a marginal reduction of the cell viability. Incubated with 100 % eluate concentration the reduction was less than 15 % cell viability. Three PEHGs caused a reduction of cell viability from 0% (PEHG 2 and 7) to 10 % (PEHG5) with increasing eluate concentration (see Figure 1 ).
Figure 1:
Relative cell viability of L929 mouse fibroblasts after 48 h cultivation in PEHG eluate dilutions of decreasing concentrations compared to the pure cell culture medium control (n = 4, mean ± SEM, ***p < 0.001).
Cell viability in HHG eluates
The HHGs pNIPAAm and PIL/pNIPAAm 50/50wt % cause only a minimal reduction of the cell viability. Marginal inferior PIL decreases cell viability to 60% (see Figure 2 ). 
Discussion and perspective
The initial biological evaluation revealed an excellent in vitro biocompatibility for the predominant part of the PEHGs (PEGH 1, 3, 4, 6, 7, 8, 9) as well as the HHGs PIL, pNIPAAm and PIL/pNIPAAm 50/50wt %. Concerning their biocompatibility the HGs of this study can compete with hyaluronic acid or alginate based HGs, which exhibit longstanding clinical use [13, 14] .
Although a cytotoxic effect of the HGs 2, 5 and 7 has been proven, they should not be completely rejected. Polymersation and washing procedure might be optimsed to pass successfully a re-evaluation.
Despite the expected negative effect of the rather toxic anions (Br -or Cl -), the hydrogels exhibit a remarkable performance within the Cell viability assay. These preliminary findings build a basis for further in depth investigations by in vitro direct contact tests, examining growth behavior and cell morphological criteria. Moreover the HGs should be tested with cell types, representative for the corresponding site of transplantation. Indeed the biocompatibility is one key prerequisite for clinical practice but there are other crucial requirements for biomedical applications such as thermic, mechanic or viscoelastic properties in swollen and in un-swollen state. Likewise the drug incorporation as well as its releasing kinetics plays a decisive role in the selection process of the promising candidates.
Conclusion
The preliminary findings of this work underline the excellent suitability for the majority of the evaluated HGs for biomedical applications and revealed some promising candidates for the development of drug depots for implants of versatile fields of application.
